Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Section 6 of 6

References

199 sources

  1. American Psychological Association Mental and Behavioral Health Registry measures page (2026) (opens in a new tab)
  2. Archer et al. (2012) (opens in a new tab)
  3. Arikci et al. (2025) (opens in a new tab)
  4. Baldwin et al. (2014) (opens in a new tab)
  5. Bandelow (2006) (opens in a new tab)
  6. Bandelow et al. (2015) (opens in a new tab)
  7. Bandelow et al. (2023) (opens in a new tab)
  8. Batelaan et al. (2016) (opens in a new tab)
  9. Batelaan et al. (2017) (opens in a new tab)
  10. Becker et al. (2023) (opens in a new tab)
  11. Becker et al. (2025) (opens in a new tab)
  12. Bentley et al. (2016) (opens in a new tab)
  13. Berger et al. (2011) (opens in a new tab)
  14. BrainFutures CPT and HCPCS coding guide (2023) (opens in a new tab)
  15. Bruce et al. (2005) (opens in a new tab)
  16. BuSpar prescribing information (2010) (opens in a new tab)
  17. Carhart-Harris and Nutt (2017) (opens in a new tab)
  18. Carl et al. (2020) (opens in a new tab)
  19. Chessick et al. (2006) (opens in a new tab)
  20. ClinicalTrials.gov NCT00920387 (opens in a new tab)
  21. ClinicalTrials.gov NCT00920387 results (opens in a new tab)
  22. ClinicalTrials.gov NCT03153579 (opens in a new tab)
  23. ClinicalTrials.gov NCT05407064 (opens in a new tab)
  24. ClinicalTrials.gov NCT05407064 results (opens in a new tab)
  25. ClinicalTrials.gov NCT05964647 (opens in a new tab)
  26. ClinicalTrials.gov NCT06741228 (opens in a new tab)
  27. ClinicalTrials.gov NCT06809595 (opens in a new tab)
  28. CMS CY 2020 Physician Fee Schedule final rule (2019) (opens in a new tab)
  29. CMS Use of High-Risk Medications in Older Adults eCQM flow (2025) (opens in a new tab)
  30. Costello et al. (2019) (opens in a new tab)
  31. COVID-19 Mental Disorders Collaborators (2021) (opens in a new tab)
  32. CTIS 2024-513572-17-00 (opens in a new tab)
  33. Cubała (2026) (opens in a new tab)
  34. Cuijpers et al. (2014) (opens in a new tab)
  35. Cymbalta prescribing information (2023) (opens in a new tab)
  36. de Vries et al. (2018) (opens in a new tab)
  37. Definium Therapeutics corporate presentation (2026) (opens in a new tab)
  38. Definium Therapeutics executive order statement (2026) (opens in a new tab)
  39. Definium Therapeutics expanded access policy (2025) (opens in a new tab)
  40. Definium Therapeutics first quarter 2026 results announcement (2026) (opens in a new tab)
  41. Definium Therapeutics Form 10-K (2026) (opens in a new tab)
  42. Definium Therapeutics Form 8-K name change (2026) (opens in a new tab)
  43. Definium Therapeutics full-year 2025 results announcement (2026) (opens in a new tab)
  44. Definium Therapeutics GAD fact sheet (2026) (opens in a new tab)
  45. Definium Therapeutics Investor and Analyst Day announcement (2026) (opens in a new tab)
  46. Definium Therapeutics Investor and Analyst Day presentation (2026) (opens in a new tab)
  47. Definium Therapeutics January 2026 corporate presentation (2026) (opens in a new tab)
  48. Definium Therapeutics LSD fact sheet (2026) (opens in a new tab)
  49. Definium Therapeutics May 2026 corporate presentation (2026) (opens in a new tab)
  50. Definium Therapeutics MDD Breakthrough Therapy designation announcement (2026) (opens in a new tab)
  51. Definium Therapeutics NEI Fall Congress announcement (2026) (opens in a new tab)
  52. Definium Therapeutics Panorama topline presentation (2026) (opens in a new tab)
  53. Definium Therapeutics Panorama topline results announcement (2026) (opens in a new tab)
  54. Definium Therapeutics rebrand announcement (2026) (opens in a new tab)
  55. Definium Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
  56. Definium Therapeutics third quarter 2026 earnings call transcript (2026) (opens in a new tab)
  57. Definium Therapeutics third quarter 2026 results announcement (2026) (opens in a new tab)
  58. Definium Therapeutics third quarter Form 10-Q (2026) (opens in a new tab)
  59. Definium Therapeutics ticker change announcement (2026) (opens in a new tab)
  60. Definium Therapeutics Voyage topline presentation (2026) (opens in a new tab)
  61. Definium Therapeutics Voyage topline results announcement (2026) (opens in a new tab)
  62. Definium Therapeutics Wired for Worry announcement (2026) (opens in a new tab)
  63. DeGeorge et al. (2022) (opens in a new tab)
  64. Dieleman et al. (2020) (opens in a new tab)
  65. Dolder et al. (2017) (opens in a new tab)
  66. Domschke et al. (2024) (opens in a new tab)
  67. Duong et al. (2024a) (opens in a new tab)
  68. Duong et al. (2024b) (opens in a new tab)
  69. Duong et al. (2024c) (opens in a new tab)
  70. Duong et al. (2024d) (opens in a new tab)
  71. Duong et al. (2024e) (opens in a new tab)
  72. Duong et al. (2026) (opens in a new tab)
  73. eCFR 21 CFR 1308.11 (opens in a new tab)
  74. Effexor XR prescribing information (2023) (opens in a new tab)
  75. EMA Lyrica product information (2026) (opens in a new tab)
  76. Etkin et al. (2009) (opens in a new tab)
  77. Ettman et al. (2025) (opens in a new tab)
  78. Executive Office of the President (2026) (opens in a new tab)
  79. FDA benzodiazepine boxed warning (2020) (opens in a new tab)
  80. FDA psychedelic drugs clinical investigations guidance (2026) (opens in a new tab)
  81. Ferries et al. (2025) (opens in a new tab)
  82. Ferries et al. (2026) (opens in a new tab)
  83. Fonzo and Etkin (2017) (opens in a new tab)
  84. Frokjaer et al. (2008) (opens in a new tab)
  85. Gasser et al. (2014) (opens in a new tab)
  86. Gasser et al. (2015) (opens in a new tab)
  87. Generoso et al. (2017) (opens in a new tab)
  88. Gomez et al. (2018) (opens in a new tab)
  89. Gonçalves and Byrne (2012) (opens in a new tab)
  90. Goodwin et al. (2020) (opens in a new tab)
  91. Grant et al. (2005) (opens in a new tab)
  92. Grant et al. (2009) (opens in a new tab)
  93. Greenberg et al. (1999) (opens in a new tab)
  94. Guaiana et al. (2010) (opens in a new tab)
  95. Hamilton (1959) (opens in a new tab)
  96. Harrewijn et al. (2021) (opens in a new tab)
  97. Healthmonix 2026 Mental and Behavioral Health Registry announcement (2026) (opens in a new tab)
  98. Hettema et al. (2001) (opens in a new tab)
  99. Hidalgo et al. (2007) (opens in a new tab)
  100. Hoffman et al. (2008) (opens in a new tab)
  101. Holze et al. (2019) (opens in a new tab)
  102. Holze et al. (2021) (opens in a new tab)
  103. Holze et al. (2022a) (opens in a new tab)
  104. Holze et al. (2022b) (opens in a new tab)
  105. Holze et al. (2023) (opens in a new tab)
  106. Holze et al. (2024a) (opens in a new tab)
  107. Holze et al. (2024b) (opens in a new tab)
  108. HRA Phase 1 PK study of MM-120 in healthy volunteers (2023) (opens in a new tab)
  109. HRA Phase 1 PK study of MM-120 under fed and fasted conditions (2024) (opens in a new tab)
  110. ICER esketamine final evidence report (2019) (opens in a new tab)
  111. ISRCTN ISRCTN11052603 (opens in a new tab)
  112. ISRCTN ISRCTN15997848 (opens in a new tab)
  113. Jacobsen et al. (2026) (opens in a new tab)
  114. Janssen SPRAVATO prescribing information (2025) (opens in a new tab)
  115. Kanwar et al. (2013) (opens in a new tab)
  116. Katzman et al. (2014) (opens in a new tab)
  117. Kessler et al. (2005a) (opens in a new tab)
  118. Kessler et al. (2005b) (opens in a new tab)
  119. Kessler et al. (2008) (opens in a new tab)
  120. Kessler et al. (2012) (opens in a new tab)
  121. Konnopka and König (2020) (opens in a new tab)
  122. Kroenke et al. (2007) (opens in a new tab)
  123. Levey et al. (2020) (opens in a new tab)
  124. Lexapro prescribing information (2024) (opens in a new tab)
  125. Louie (2026) (opens in a new tab)
  126. Luethi et al. (2019) (opens in a new tab)
  127. Lyrica prescribing information (2025) (opens in a new tab)
  128. Malberg et al. (2026) (opens in a new tab)
  129. Maneeton et al. (2016) (opens in a new tab)
  130. Martens et al. (2010) (opens in a new tab)
  131. Mavranezouli et al. (2013) (opens in a new tab)
  132. Meier et al. (2016) (opens in a new tab)
  133. MindMed APA presentation announcement (2024) (opens in a new tab)
  134. MindMed Breakthrough Therapy designation announcement (2024) (opens in a new tab)
  135. MindMed Catalent license announcement (2023) (opens in a new tab)
  136. MindMed corporate presentation (2025) (opens in a new tab)
  137. MindMed end-of-phase 2 meeting announcement (2024) (opens in a new tab)
  138. MindMed full-year 2024 results announcement (2025) (opens in a new tab)
  139. MindMed IND clearance announcement (2022) (opens in a new tab)
  140. MindMed IND clinical hold announcement (2021) (opens in a new tab)
  141. MindMed Innovation Passport announcement (2024) (opens in a new tab)
  142. MindMed JAMA publication announcement (2025) (opens in a new tab)
  143. MindMed Liechti and Holze anxiety trial announcement (2022) (opens in a new tab)
  144. MindMed MMED008 protocol (2023) (opens in a new tab)
  145. MindMed MMED008 statistical analysis plan (2023) (opens in a new tab)
  146. MindMed ODT patent announcement (2024) (opens in a new tab)
  147. MindMed Panorama first patient dosed announcement (2025) (opens in a new tab)
  148. MindMed Phase 2b and ODT bridging presentation (2024) (opens in a new tab)
  149. MindMed Phase 2b enrollment completion announcement (2023) (opens in a new tab)
  150. MindMed Phase 2b first patient dosed announcement (2022) (opens in a new tab)
  151. MindMed Phase 2b topline results announcement (2023) (opens in a new tab)
  152. MindMed suicidal ideation study announcement (2025) (opens in a new tab)
  153. MindMed third quarter 2025 results announcement (2025) (opens in a new tab)
  154. MindMed Voyage first patient dosed announcement (2024) (opens in a new tab)
  155. Munir and Takov (2022) (opens in a new tab)
  156. Mustafa et al. (2024) (opens in a new tab)
  157. Muthukumaraswamy et al. (2021) (opens in a new tab)
  158. National Institute of Mental Health generalized anxiety disorder statistics (opens in a new tab)
  159. NCQA Use of High-Risk Medications in Older Adults measure description (opens in a new tab)
  160. Newman et al. (2013) (opens in a new tab)
  161. NICE clinical guideline CG113 (2011) (opens in a new tab)
  162. Olatunji et al. (2007) (opens in a new tab)
  163. Patriquin and Mathew (2017) (opens in a new tab)
  164. Paxil prescribing information (2026) (opens in a new tab)
  165. Penninx et al. (2021) (opens in a new tab)
  166. Plummer et al. (2016) (opens in a new tab)
  167. Powdar et al. (2025) (opens in a new tab)
  168. Purves et al. (2020) (opens in a new tab)
  169. Revicki et al. (2012) (opens in a new tab)
  170. Ringeisen et al. (2023) (opens in a new tab)
  171. Robison et al. (2025) (opens in a new tab)
  172. Robison et al. supplementary appendix (2025) (opens in a new tab)
  173. Roest et al. (2010) (opens in a new tab)
  174. Ross and Soeteman (2020) (opens in a new tab)
  175. Roy-Byrne et al. (2010) (opens in a new tab)
  176. RTI International (2023) (opens in a new tab)
  177. Rubio and Lopez-Ibor (2007) (opens in a new tab)
  178. Ruscio et al. (2017) (opens in a new tab)
  179. Seroquel XR prescribing information (2025) (opens in a new tab)
  180. Shirneshan et al. (2013) (opens in a new tab)
  181. Slee et al. (2019) (opens in a new tab)
  182. Soares (2025) (opens in a new tab)
  183. Solmi et al. (2022) (opens in a new tab)
  184. Spitzer et al. (2006) (opens in a new tab)
  185. Stein and Sareen (2015) (opens in a new tab)
  186. Straumann et al. (2023) (opens in a new tab)
  187. Strawn et al. (2018) (opens in a new tab)
  188. Strom et al. (2026) (opens in a new tab)
  189. Szuhany and Simon (2022) (opens in a new tab)
  190. Terlizzi and Villarroel (2020) (opens in a new tab)
  191. Terlizzi and Zablotsky (2024) (opens in a new tab)
  192. Thielking et al. (2026) (opens in a new tab)
  193. Tucker et al. (2018) (opens in a new tab)
  194. USPSTF anxiety screening recommendation (2023) (opens in a new tab)
  195. Vistaril prescribing information (2014) (opens in a new tab)
  196. Vizeli et al. (2021) (opens in a new tab)
  197. Xanax prescribing information (2023) (opens in a new tab)
  198. Yang et al. (2021) (opens in a new tab)
  199. Yonkers et al. (1996) (opens in a new tab)